Amgen: Ovarian Neoplasms trials

The registry lists 10 Ovarian Neoplasms studies with Amgen as lead sponsor. 0 are open to participants now and 2 have results posted.

Phase 1 3Phase 2 3Phase 3 4No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced AnaemiaCompletedNCT01444456Results posted
• Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or LymphomaCompletedNCT00531284Phase 1/2Results posted
• Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast CancerActive, not recruitingNCT03937154Phase 3
• TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian CancerTerminatedNCT01493505Phase 3
• AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)TerminatedNCT01281254Phase 3
• Study of AMG 386 in Combination With Paclitaxel and Carboplatin in Subjects With Ovarian CancerCompletedNCT01253681Phase 1
• TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube CancerCompletedNCT01204749Phase 3
• AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CRCompletedNCT00770536Phase 1
• Evaluating Pegfilgrastim and a Multi-Day Topotecan Regimen in Subjects With Relapsed or Refractory Ovarian CancerCompletedNCT00113789Phase 2
• Study of T900607-Sodium in Previously Treated Patients With Ovarian Cancer.Status unknownNCT00043446Phase 2